Abeona Therapeutics Inc (NASDAQ: ABEO)’s stock price has decreased by -0.19 compared to its previous closing price of 5.28. However, the company has seen a 7.11% increase in its stock price over the last five trading sessions. seekingalpha.com reported 2025-04-21 that Abeona’s pz-cel gene therapy shows the most durable wound healing in RDEB patients with no treatment related severe adverse events. There have been no instances of Squamous Cell Carcinoma. The FDA’s previous Complete Response Letter focused on manufacturing and control issues. Since those questions have been answered thoroughly, an approval is likely by April 29th. Pz-cel offers a durable, one-time treatment. This reduces long-term costs compared to VYJUVEK which requires ongoing weekly applications.
Is It Worth Investing in Abeona Therapeutics Inc (NASDAQ: ABEO) Right Now?
ABEO has 36-month beta value of 1.61. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ABEO is 43.12M, and currently, short sellers hold a 5.13% ratio of that float. The average trading volume of ABEO on April 23, 2025 was 518.73K shares.
ABEO’s Market Performance
ABEO stock saw an increase of 7.11% in the past week, with a monthly gain of 2.93% and a quarterly increase of 2.53%. The volatility ratio for the week is 6.30%, and the volatility levels for the last 30 days are 8.00% for Abeona Therapeutics Inc (ABEO). The simple moving average for the last 20 days is 10.52% for ABEO stock, with a simple moving average of -5.27% for the last 200 days.
Analysts’ Opinion of ABEO
Many brokerage firms have already submitted their reports for ABEO stocks, with Oppenheimer repeating the rating for ABEO by listing it as a “Outperform.” The predicted price for ABEO in the upcoming period, according to Oppenheimer is $16 based on the research report published on March 05, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ABEO reach a price target of $15. The rating they have provided for ABEO stocks is “Buy” according to the report published on July 03rd, 2024.
Stifel gave a rating of “Buy” to ABEO, setting the target price at $21 in the report published on May 30th of the previous year.
ABEO Trading at 2.39% from the 50-Day Moving Average
After a stumble in the market that brought ABEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.27% of loss for the given period.
Volatility was left at 8.00%, however, over the last 30 days, the volatility rate increased by 6.30%, as shares surge +6.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.42% lower at present.
During the last 5 trading sessions, ABEO rose by +8.33%, which changed the moving average for the period of 200-days by +17.40% in comparison to the 20-day moving average, which settled at $4.77. In addition, Abeona Therapeutics Inc saw -5.39% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABEO starting from Seshadri Vishwas, who sale 25,000 shares at the price of $4.78 back on Mar 31 ’25. After this action, Seshadri Vishwas now owns 1,355,322 shares of Abeona Therapeutics Inc, valued at $119,500 using the latest closing price.
Seshadri Vishwas, the Officer of Abeona Therapeutics Inc, proposed sale 25,000 shares at $4.78 during a trade that took place back on Mar 31 ’25, which means that Seshadri Vishwas is holding shares at $119,560 based on the most recent closing price.
Stock Fundamentals for ABEO
The total capital return value is set at -0.7. Equity return is now at value -216.57, with -73.71 for asset returns.
Based on Abeona Therapeutics Inc (ABEO), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at -2.43. The debt to equity ratio resting at 0.52. The interest coverage ratio of the stock is -15.26.
Currently, EBITDA for the company is -64.21 million with net debt to EBITDA at 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.08.
Conclusion
To put it simply, Abeona Therapeutics Inc (ABEO) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
